Progress in neuro-imaging of brain tumors

Current Opinion in Oncology

Volumn 28, Issue 6, 2016, Pages 484-493

  Castellano, Antonella ^a   Falini, Andrea ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Diffusion MRI; Magnetic resonance imaging; Magnetic resonance spectroscopy; Perfusion weighted imaging; Radiogenomics

Indexed keywords

ARTERIAL SPIN LABELING; BRAIN TUMOR; CLINICAL ASSESSMENT; DIFFUSION WEIGHTED IMAGING; DISEASE CLASSIFICATION; DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING; GENOMICS; HEMODYNAMICS; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVIEW; TUMOR DIAGNOSIS; DIAGNOSTIC IMAGING; PROCEDURES;

BRAIN NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROIMAGING;

EID: 84988624684     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000328     Document Type: Review

References (56)

1. Reardon DA, Wen PY. Glioma in 2014: unravelling tumour heterogeneityimplications for therapy. Nat Rev Clin Oncol 2015; 12:69-70.
2. Cancer Genome Atlas Research Network. Brat DJ, Verhaak RG, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015; 372:2481-2498.
3. Wen PY, Reardon DA. Neuro-oncology in 2015: progress in glioma diagnosis, classification and treatment. Nat Rev Neurol 2016; 12:69-70.
4. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131:803-820.
5. Pope WB. Genomics of brain tumor imaging. Neuroimaging Clin N Am 2015; 25:105-119.
6. Ellingson BM, Lai A, Harris RJ, et al. Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol 2013; 34:533-540.
7. VerhaakRG,HoadleyKA, PurdomE, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17:98-110.
8. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9:157-173.
9. Sandmann T, Bourgon R, Garcia J, et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the avaglio trial. J Clin Oncol 2015; 33:2735-2744.
10. Naeini KM, Pope WB, Cloughesy TF, et al. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro Oncol 2013; 15:626-634.
11. Korfiatis P, Kline TL, Coufalova L, et al. MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas. Med Phys 2016; 43:2835-2844.
12. Gevaert O, Mitchell LA, Achrol AS, et al. Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. Radiology 2015; 276:313.
13. Miloushev VZ, Chow DS, Filippi CG. Meta-Analysis of diffusion metrics for the prediction of tumor grade in gliomas. AJNR Am J Neuroradiol 2015; 36:302-308.
14. Sternberg EJ, Lipton ML, Burns J. Utility of diffusion tensor imaging in evaluation of the peritumoral region in patients with primary and metastatic brain tumors. AJNR Am J Neuroradiol 2014; 35:439-444.
15. Castellano A, Donativi M, Ruda R, et al. Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps. Eur Radiol 2016; 26:1263-1273.
16. Tietze A, Hansen MB, Ostergaard L, et al. Mean diffusional kurtosis in patients with glioma: initial results with a fast imaging method in a clinical setting. AJNR Am J Neuroradiol 2015; 36:1472-1478.
17. Bai Y, Lin Y, Tian J, et al. Grading of gliomas by using monoexponential, biexponential, and stretched exponential diffusion-weighted MR imaging and diffusion kurtosis MR imaging. Radiology 2016; 278:496-504.
18. Wen Q, Kelley DA, Banerjee S, et al. Clinically feasible NODDI characterization of glioma using multiband EPI at 7 T. Neuroimage Clin 2015; 9:291-299.
19. Caverzasi E, Papinutto N, Castellano A, et al. Neurite orientation dispersion and density imaging color maps to characterize brain diffusion in neurologic disorders. J Neuroimaging 2016; 26:494-498.
20. Castellano A, Bello L, Michelozzi C, et al. Role of diffusion tensor magnetic resonance tractography in predicting the extent of resection in glioma surgery. Neuro Oncol 2012; 14:192-202.
21. Bello L, Gambini A, Castellano A, et al. Motor and language DTI Fiber Tracking combined with intraoperative subcortical mapping for surgical removal of gliomas. Neuroimage 2008; 39:369-382.
22. Ohue S, Kohno S, Inoue A, et al. Accuracy of diffusion tensor magnetic resonance imaging-based tractography for surgery of gliomas near the pyramidal tract: a significant correlation between subcortical electrical stimulation and postoperative tractography. Neurosurgery 2012; 70:283-293.
23. Caverzasi E, Hervey-Jumper SL, Jordan KM, et al. Identifying preoperative language tracts and predicting postoperative functional recovery using HARDI q-ball fiber tractography in patients with gliomas. J Neurosurg 2016; 125:33-45.
24. Mormina E, Longo M, Arrigo A, et al. MRI tractography of corticospinal tract and arcuate fasciculus in high-grade gliomas performed by constrained spherical deconvolution: qualitative and quantitative analysis. AJNR Am J Neuroradiol 2015; 36:1853-1858.
25. Kuhnt D, Bauer MH, Sommer J, et al. Optic radiation fiber tractography in glioma patients based on high angular resolution diffusion imaging with compressed sensing compared with diffusion tensor imaging-initial experience. PLoS One 2013; 8:e70973.
26. Griffith B, Jain R. Perfusion imaging in neuro-oncology: basic techniques and clinical applications. Radiol Clin North Am 2015; 53:497-511.
27. Essig M, Nguyen TB, Shiroishi MS, et al. Perfusion MRI: the five most frequently asked clinical questions. AJR Am J Roentgenol 2013; 201:W495-W510.
28. Hu LS, Kelm Z, Korfiatis P, et al. Impact of software modeling on the accuracy of perfusion MRI in glioma. AJNR Am J Neuroradiol 2015; 36:2242-2249.
29. Shiroishi MS, Castellazzi G, Boxerman JL, et al. Principles of T2-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging. J Magn Reson Imaging 2015; 41:296-313.
30. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibilityweighted contrast-enhanced perfusion MR imaging. Radiology 2008; 247:490-498.
31. Kickingereder P, Sahm F, Radbruch A, et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is noninvasively predictable with rCBV imaging in human glioma. Sci Rep 2015; 5:16238.
32. Kickingereder P, Wiestler B, Burth S, et al. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro Oncol 2015; 17:1139-1147.
33. Kickingereder P, Radbruch A, Burth S, et al. MR perfusion-derived hemodynamic parametric response mapping of bevacizumab efficacy in recurrent glioblastoma. Radiology 2016; 279:542-552.
34. Radbruch A, Fladt J, Kickingereder P, et al. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. Neuro Oncol 2015; 17:151-159.
35. Wang S, Martinez-Lage M, Sakai Y, et al. Differentiating tumor progression from pseudoprogression in patients with glioblastomas using diffusion tensor imaging and dynamic susceptibility contrast MRI. AJNR Am J Neuroradiol 2016; 37:28-36.
36. Heye AK, Culling RD, Valdes Hernandez Mdel C, et al. Assessment of bloodbrain barrier disruption using dynamic contrast-enhanced MRI. A systematic review. Neuroimage Clin 2014; 6:262-274.
37. Arevalo-Perez J, Thomas AA, Kaley T, et al. T1-weighted dynamic contrastenhanced MRI as a noninvasive biomarker of epidermal growth factor receptor vIII status. AJNR Am J Neuroradiol 2015; 36:2256-2261.
38. Politi LS, Brugnara G, Castellano A, et al. T1-weighted dynamic contrastenhanced MRI is a noninvasive marker of epidermal growth factor receptor vIII status in cancer stem cell-derived experimental glioblastomas. AJNR Am J Neuroradiol 2016; 37:E49-E51.
39. Nguyen TB, Cron GO, Perdrizet K, et al. Comparison of the diagnostic accuracy of DSC-And dynamic contrast-enhanced MRI in the preoperative grading of astrocytomas. AJNR Am J Neuroradiol 2015; 36:2017-2022.
40. Santarosa C, Castellano A, Conte GM, et al. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis. Eur J Radiol 2016; 85:1147-1156.
41. Falk A, Fahlstrom M, Rostrup E, et al. Discrimination between glioma grades II and III in suspected low-grade gliomas using dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology 2014; 56:1031-1038.
42. Alcaide-Leon P, Pareto D, Martinez-Saez E, et al. Pixel-by-pixel comparison of volume transfer constant and estimates of cerebral blood volume from dynamic contrast-enhanced and dynamic susceptibility contrast-enhanced MR imaging in high-grade gliomas. AJNR Am J Neuroradiol 2015; 36:871-876.
43. Mills SJ, du Plessis D, Pal P, et al. Mitotic activity in glioblastoma correlates with estimated extravascular extracellular space derived from dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2016; 37:811-817.
44. Nguyen TB, Cron GO, Mercier JF, et al. Preoperative prognostic value of dynamic contrast-enhanced MRI-derived contrast transfer coefficient and plasma volume in patients with cerebral gliomas. AJNR Am J Neuroradiol 2015; 36:63-69.
45. Qiao XJ, Ellingson BM, Kim HJ, et al. Arterial spin-labeling perfusion MRI stratifies progression-free survival and correlates with epidermal growth factor receptor status in glioblastoma. AJNR Am J Neuroradiol 2015; 36:672-677.
46. Chaumeil MM, Lupo JM, Ronen SM. Magnetic resonance (MR) metabolic imaging in glioma. Brain Pathol 2015; 25:769-780.
47. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012; 18:624-629.
48. Andronesi OC, Kim GS, Gerstner E, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 2012; 4:116ra4.
49. Andronesi OC, Loebel F, Bogner W, et al. Treatment response assessment in IDH-mutant glioma patients by noninvasive 3D functional spectroscopic mapping of 2-hydroxyglutarate. Clin Cancer Res 2016; 22:1632-1641.
50. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013; 340:626-630.
51. Pellegatta S, Valletta L, Corbetta C, et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun 2015; 3:4.
52. de la Fuente MI, Young RJ, Rubel J, et al. Integration of 2-hydroxyglutarateproton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro Oncol 2016; 18:283-290.
53. Balchandani P, Naidich TP. Ultra-high-field MR neuroimaging. AJNR Am J Neuroradiol 2015; 36:1204-1215.
54. Bian W, Banerjee S, Kelly DA, et al. Simultaneous imaging of radiationinduced cerebral microbleeds, arteries and veins, using a multiple gradient echo sequence at 7 Tesla. J Magn Reson Imaging 2015; 42:269-279.
55. Nagel AM, Bock M, Hartmann C, et al. The potential of relaxation-weighted sodium magnetic resonance imaging as demonstrated on brain tumors. Invest Radiol 2011; 46:539-547.
56. Biller A, Badde S, Nagel A, et al. Improved brain tumor classification by sodium MR imaging: prediction of IDH mutation status and tumor progression. AJNR Am J Neuroradiol 2016; 37:66-73.